<table class="naaccr-summary-table naaccr-borders">
  <tr>
    <th class="naaccr-summary-header naaccr-borders">Item #</th>
    <th class="naaccr-summary-header naaccr-borders">Length</th>
    <th class="naaccr-summary-header naaccr-borders">Source of Standard</th>
    <th class="naaccr-summary-header naaccr-borders">Year Implemented</th>
    <th class="naaccr-summary-header naaccr-borders">Version Implemented</th>
    <th class="naaccr-summary-header naaccr-borders">Year Retired</th>
    <th class="naaccr-summary-header naaccr-borders">Version Retired</th>
  </tr>
  <tr>
    <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">1065</td>
    <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">4</td>
    <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">AJCC</td>
    <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">2021</td>
    <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">21</td>
    <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered"></td>
    <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered"></td>
  </tr>
</table>

<br/><strong>NAACCR XML</strong>: Tumor.ajccTnmPostTherapyClinNSuffix<br/><br/>


<div class='content chap10-para-head'><strong><strong>Description</strong></strong></div><div class='content chap10-para'>Detailed site-specific codes for the post therapy clinical (yc) N category suffix as defined by AJCC.<br /><br />Clinical, pathological, and post therapy yc and yp stage data are given four separate areas in the NAACCR Data Exchange Record Layout.</div><div class='content chap10-para-head'><strong><strong>Rationale</strong></strong></div><div class='content chap10-para'>CoC requires that AJCC TNM staging be used in its approved cancer programs. AJCC developed its staging system for evaluating trends in the treatment and control of cancer. This staging is used by physicians to estimate prognosis, to plan treatment, to evaluate new types of therapy, to analyze outcome, to design follow-up strategies, and to assess early detection results.</div><div class='content chap10-para'><strong>Codes</strong></div><div class='content chap10-para'><table><tr class='code-row'><td class='code-nbr'>(sn)</td><td class='code-desc'>Sentinel node procedure with or without FNA or core needle biopsy</td></tr><tr class='code-row'><td class='code-nbr'>(f)</td><td class='code-desc'>FNA or core needle biopsy only</td></tr><tr class='code-row'><td class='code-nbr'>Blank</td><td class='code-desc'>No suffix needed or appropriate; not recorded</td></tr><tr class='code-row'><td class='code-nbr'></td><td class='code-desc'> </td></tr></table></div>